Group 1 - The core point of the article is that Guoyao Modern (SH 600420) held a temporary board meeting on September 22, 2025, to discuss the addition of members to the Strategic and Investment Committee [1] - For the fiscal year 2024, Guoyao Modern's revenue composition is as follows: formulations account for 49.84%, intermediates and raw materials account for 47.53%, other businesses account for 2.44%, and health-related businesses account for 0.19% [1] - As of the report, Guoyao Modern has a market capitalization of 14.6 billion yuan [1]

Core Viewpoint - The company Guoyao Modern (600420.SH) has received approval from the National Medical Products Administration for its subsidiary Guoyao Group Rongsheng Pharmaceutical Co., Ltd. to expand the specifications of its Vitamin B6 injection and pass the consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Guoyao Modern's subsidiary has been granted a drug approval notice for Vitamin B6 injection, allowing for increased specifications [1] - The approval includes the issuance of a drug approval number, indicating regulatory compliance and market readiness [1] Group 2: Product Information - Vitamin B6 injection is indicated for the prevention and treatment of Vitamin B6 deficiency, including conditions such as isoniazid poisoning, pregnancy-related issues, radiation sickness, and chemotherapy-induced vomiting [1] - The product is also used for total parenteral nutrition and to address nutritional deficiencies due to inadequate intake or progressive weight loss [1] - Additional indications include situations requiring increased Vitamin B6 intake and congenital Vitamin B6 dependency syndrome in newborns [1]

Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), received approval from the National Medical Products Administration for a supplemental application regarding Vitamin B6 injection, allowing for an increase in specifications and passing the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approval of the Vitamin B6 injection's new specifications and the successful consistency evaluation will facilitate future market expansion and sales for the product [1] - The recent developments are not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), has received approval from the National Medical Products Administration for a supplemental application regarding Vitamin B6 injection, allowing for an increase in specifications and passing the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approved Vitamin B6 injection is indicated for the prevention and treatment of Vitamin B6 deficiency, management of isoniazid poisoning, and can also be used for nausea caused by pregnancy, radiation sickness, and chemotherapy, as well as seborrheic dermatitis [1] - The injection is also used for total parenteral nutrition and supplementation in cases of nutritional deficiency due to inadequate intake, as well as for progressive weight loss situations [1] - Additional indications include situations requiring increased Vitamin B6 intake and congenital Vitamin B6 dependency syndrome in newborns [1]

Core Viewpoint - China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a supplemental application for Vitamin B6 injection, allowing for an increase in specifications and passing the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approval of the Vitamin B6 injection will facilitate market expansion and sales for the product in the future [1] - The recent developments are not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - The approval of the new specification for Vitamin B6 injection by the National Medical Products Administration is expected to facilitate market expansion and sales for the company, although it will have a limited impact on current operating performance [1] Company Summary - The company, under its wholly-owned subsidiary Guoyao Rongsheng, received a notification for the approval of a supplementary application for Vitamin B6 injection, allowing for a new specification of 1ml:0.1g [1] - The cumulative R&D investment for this project has reached 4.0885 million yuan [1] Industry Summary - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency and other related indications [1] - The projected sales revenue for this drug in public medical institutions nationwide is approximately 304 million yuan for the year 2024 [1]

Core Viewpoint - The company actively utilizes synthetic biology and other new technologies to optimize existing product processes and develop new applications, aiming to enhance product quality, strengthen cost competitiveness, and reduce pollutant emissions [1] Group 1 - The company participated in the "Communicating Value and Building Confidence for the Future" event, which is part of the 2025 Shanghai-listed companies collective reception day and mid-term performance briefing [1] - The company emphasizes the importance of continuous improvement in product processes and research and development applications [1] - The goals set by the company include improving product quality, enhancing cost competitiveness, and lowering pollutant emissions [1]

Group 1 - The core viewpoint of the news is that Guoyao Modern's stock has shown fluctuations in price and trading volume, with a recent increase of 2.00% to 11.21 CNY per share, while the company has experienced a year-to-date decline of 3.69% [1] - As of June 30, 2025, Guoyao Modern reported a revenue of 4.878 billion CNY, a year-on-year decrease of 18.16%, and a net profit attributable to shareholders of 672 million CNY, down 6.46% compared to the previous year [2] - The company has distributed a total of 1.644 billion CNY in dividends since its A-share listing, with 805 million CNY distributed over the last three years [3] Group 2 - The company has a total market capitalization of 15.035 billion CNY and a trading volume of 84.7925 million CNY, with a turnover rate of 0.57% [1] - As of June 30, 2025, the number of shareholders decreased by 2.13% to 40,000, while the average circulating shares per person increased by 2.18% to 33,571 shares [2] - The major shareholders have seen changes, with Hong Kong Central Clearing Limited exiting the top ten circulating shareholders list as of June 30, 2025 [3]

Core Points - The company Guoyao Modern has received approval from the National Medical Products Administration for the drug Enalapril Maleate Tablets (5mg) to pass the consistency evaluation of generic drug quality and efficacy [2] Group 1 - Guoyao Modern announced the receipt of the approval notice for the supplementary application of the drug [2] - The approval indicates that the drug has met the standards for quality and efficacy consistency as a generic medication [2]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), has received approval from the National Medical Products Administration for the supplementary application of Enalapril Maleate Tablets (5mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Information - Enalapril Maleate Tablets are an angiotensin-converting enzyme (ACE) inhibitor primarily used for treating essential hypertension, renovascular hypertension, and symptomatic heart failure [1] - The projected sales for Enalapril Maleate Tablets in public medical institutions and urban pharmacies in China for 2024 is estimated at RMB 164 million [1] Group 2: Financial Investment - The cumulative R&D investment for this project amounts to approximately RMB 15.37 million (unaudited) [1] - The approval of the 5mg formulation is expected to facilitate future market expansion and sales of the product [1] Group 3: Impact on Company Performance - The recent approval is not anticipated to have a significant impact on the company's current operating performance [1]